Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation
Open Access
- 15 January 2003
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 101 (2) , 469-472
- https://doi.org/10.1182/blood-2002-02-0571
Abstract
The kinetics of minimal residual disease (MRD) and chimerism were studied in 15 patients with chronic myeloid leukemia (CML) receiving nonmyeloablative stem cell transplantation (NST) and in 10 patients receiving conventional stem cell transplantation (CST). All NST patients showed T-cell mixed chimerism (MC) while granulocyte and B-cell MC occurred in 80% and 60% of the NST patients, respectively. In CST patients, T-cell MC was detected in 5 patients, of whom 3 were mixed only during the first month. MRD was detected in all NST patients. During the first 3 months the median BCR-ABL/ABL ratio was 0.2% in NST patients compared with 0.01% in CST patients (P < .01). However, 12 months after transplantation, the percentage of reverse transcriptase–polymerase chain reaction (RT-PCR)–positive patients was 20% in NST patients and 50% in CST patients. In conclusion, molecular remission can be induced in most patients after NST, albeit with different kinetics from CST.Keywords
This publication has 21 references indexed in Scilit:
- Mixed chimaerism is common at the time of acute graft‐versus‐host disease and disease response in patients receiving non‐myeloablative conditioning and allogeneic stem cell transplantationBritish Journal of Haematology, 2001
- Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantationLeukemia, 2001
- The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantationBlood, 2001
- Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsBlood, 2001
- Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?British Journal of Haematology, 2000
- Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantationBone Marrow Transplantation, 1999
- Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative studyLeukemia & Lymphoma, 1996
- Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapseBritish Journal of Haematology, 1993
- PERSISTENCE OF bcr-abl GENE EXPRESSION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASETransplantation, 1991
- Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic PhaseAnnals of Internal Medicine, 1988